Antabio is a France-based biopharma company dedicated to the discovery and development of first-in-class molecule compounds to treat severe infections caused by multi-drug resistant bacterial pathogens.
Antabio – next generation of antibacterial drugs
Antabio uses proprietary in vitro technologies and extensive bacterial disease know-how to develop the next generation of antibacterial drugs targeting severe and difficult-to-treat infections caused by major Gram-negative pathogens. These include life-threatening infections caused by multi-drug resistant pathogens for which there are no available treatments, e.g. metallo beta-lactamase (MBL) producer superbugs currently spreading worldwide and recalcitrant biofilms in cystic fibrosis patients. Antabio uses its proprietary technology, world-class antibacterial discovery expertise and partnering-oriented business strategy to advance novel drugs that will offer solutions to the shortfall of the current antibacterial arsenal. Antabio’s expertise relies on new chemical entities (NCEs) targeting bacterial resistance, virulence and persistence to be combined with registered antibiotics.
Current antibacterial chemotherapy is becoming increasingly inadequate due to the rise of clinical resistance, mainly related to the spread of genes encoding various carbapenemases, including the metallo ß-lactamase (MBL) enzymes of the NDM, VIM and IMP types, for which no inhibitors are currently available or under clinical development. Antabio is developing a novel, safe and efficacious inhibitor of bacterial MBLs.
Despite intensive antibiotic treatment, adaptive mechanisms such as biofilm formation allow Pseudomonas to resist both immune and antibiotic pressures, leading to recurrent exacerbations and respiratory failure. Antabio is developing an inhaled drug which can be used as an adjunct to existing antibiotic therapy and which will reduce the frequency and severity of Pseudomonas exacerbations by targeting both the virulence and persistence of biofilm-adapted infections.
Antabio is a biotech company headquartered in Toulouse (France). Management Team is composed by Marc Lemonnier, Aymeric Dugray, David Davies, Martin Everett and Delphine Ortega. Scientific Advisory Board is composed by Ken Coleman, Patrice Nordmann, Roger Echols and Jean-Denis Docquier. Antabio pursues an aggressive IP strategy to protect its drug discovery portfolio though novel composition of matter claims on selected series and claims on use of the compounds.
More about Antabio : www.antabio.com